



MEDICATION POLICY

Generic Name: Ophthalmic VEGF Inhibitors

Therapeutic Class or Brand Name: Ophthalmic VEGF Inhibitors

Applicable Drugs (if Therapeutic Class):

Avastin® (bevacizumab), Eylea® (aflibercept), Lucentis® (ranibizumab), Macugen® (pegaptanib)

Date of Origin: 8/28/15

Date Last Reviewed/Revised: 1/16/18

GPI Code: 2133502000, 8665501000, 8665505030, 8665506000

Prior Authorization Criteria (may be considered medically necessary when criteria I through III are met):

- I. Documented diagnosis of one of the following conditions A through F AND must meet criteria listed under applicable diagnosis:
 - A. Neovascular (Wet) Age-Related Macular Degeneration (AMD) AND one of criteria 1 through 4 is met:
 1. Request is for Avastin®.
 2. Request is for Eylea® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin®.
 3. Request is for Lucentis® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®.
 4. Request is for Macugen® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to TWO of the following: Avastin®, Eylea®, and Lucentis®.
 - B. Diabetic Macular Edema (DME) AND one of criteria 1 through 4 is met:
 1. Request is for Avastin®.
 2. Request is for Eylea® AND one of the following criteria a or b is met:
 - a. Documented baseline visual acuity of 20/50 or worse.
 - b. Documented trial and failure of, intolerance to, or contraindication to Avastin®
 3. Request is for Lucentis® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®.
 4. Request is for Macugen® AND criterion a is met:

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

- a. Documented trial and failure of, intolerance to, or contraindication to TWO of the following: Avastin®, Eylea®, and Lucentis®.
 - C. Macular Edema Following Retinal Vein Occlusion (RVO) AND one of criteria 1 through 3 is met:
 1. Request is for Avastin®.
 2. Request is for Eylea® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin®.
 3. Request is for Lucentis® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®.
 - D. Diabetic Retinopathy (DR) in Patients without DME AND one of criteria 1 through 2 is met:
 1. Request is for Avastin®.
 2. Request is for Lucentis® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin®.
 - E. Diabetic Retinopathy (DR) in Patients with DME AND one of criteria 1 through 3 is met:
 1. Request is for Avastin®.
 2. Request is for Eylea® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin®.
 3. Request is for Lucentis® AND criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin® and Eylea®.
 - F. Myopic Choroidal Neovascularization (mCNV) AND one of criteria 1 or 2 is met:
 1. Request is for Avastin®.
 2. Request is for Lucentis® and criterion a is met:
 - a. Documented trial and failure of, intolerance to, or contraindication to Avastin®.
- II. Minimum age requirement: 18 years old.
- III. Provider is an ophthalmologist.

Exclusion Criteria:

- Ocular or periocular infections.
- Concurrent use of one VEGF inhibitor with another VEGF inhibitor.

Other Criteria:

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

- N/A

Quantity/Days Supply Restrictions:

- Avastin®: One injection every 4 weeks.
- Eylea®:
 - AMD: One injection every 4 weeks for the first 12 weeks, followed by one injection every 8 weeks.
 - RVO: One injection every 4 weeks.
 - DME/DR: One injection every 4 weeks for the first 5 injections, followed by one injection every 8 weeks.
- Lucentis®: One injection every 4 weeks.
- Macugen®: One injection every 6 weeks.

Approval Length:

- **Authorization:**
 - mCNV:
 - Lucentis®: 3 months.
 - Avastin®: 1 year.
 - AMD, DME, RVO, DR: 1 year.
- **Re-Authorization:** An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective. Reauthorization is for the same length as the original authorization.

Appendix:

N/A

References:

1. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Age-related macular degeneration. San Francisco, CA: American Academy of Ophthalmology; 2015. Available at: www.aao.org/ppp.
2. Chakravarthy U, Williams M, AMD Guidelines Group. The Royal College of Ophthalmologists guidelines on AMD: executive summary. Eye. 2013;27:1429-31.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

3. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144-67.
4. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2016. Available at: www.aao.org/ppp.
5. Mitchell P, Wong TY for the Diabetic Macular Edema Treatment Guideline Working Group. Management paradigms for diabetic macular edema. Am J Ophthalmol. 2014;157:505-13.
6. Mitry D, Bunce C, Charteris D. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev. 2013. Jan 31;1:CD009510.
7. Braithwaite T, Nanji AA, Lindsley K, et al. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014, Issue 5. Art. No.: CD007325.
8. UpToDate®. Retinal vein occlusion: treatment. Wolters Kluwer Health. <https://www.uptodate.com>. Updated October 29, 2014. Accessed July 6, 2015.
9. Minckler D. Evidence-based ophthalmology series and content-based continuing medical education for the journal (editorial). Ophthalmology. 2000;107:9-10.
10. Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology. 2012;119:2179-88.
11. O'Malley PG. Comparative effectiveness of anti-growth factor therapies for diabetic macular edema. Arch intern Med. 2012;172:1014-5.
12. Ollendorf DA, Colby JA, Pearson SD. Comparative effectiveness of anti-VEGF agents for diabetic macular edema. Int J Technol Assess Health Care. 2013;29:392-401.
13. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014, Issue 8. Art. No.: CD005139.
14. Martin DF, Maguire MG. Treatment choice for diabetic macular edema (editorial). N Engl J Med. 2015;372:1260-1.
15. Wang W, Zhang X. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PLoS One. 2014;9:e109744.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

16. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537-48.
17. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013;156:502-10.
18. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193-1203.
19. Virgili G, Parravano M, Menchini F, et al. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014, Issue 10. Art. No.: CD007419.
20. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014, Issue 9. Art. No.: CD011230.
21. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31:654-61.
22. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120:2300-9.
23. Chakravarthy U. Bevacizumab for the treatment of neovascular age related macular degeneration (editorial). BMJ. 2010;340:c2834.
24. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-33.
25. Dakin HA, Wordsworth S, Rogers CA, et al. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomized trial. BMJ Open. 2014;4:e005094.
26. Pershing S, Enns EA, Matesic B, et al. Cost-effectiveness of treatment of diabetic macular edema. Ann Intern Med. 2014;160:18-29.
27. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-98.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

28. Silver J. Drugs for macular degeneration, price discrimination, and Medicare's responsibility not to overpay. JAMA. 2014;312:23-4.
29. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9.
30. Al Rashaed S, Rushood A. Acute bacterial endophthalmitis after intravitreal bevacizumab injection: case report and literature review. Saudi J Ophthalmol. 2013;27:55-7.
31. Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina. 2014;34:18-23.
32. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-908.
33. Sheyman AT, Cohen BZ, Friedman AH, et al. An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol. 2013;131:864-9.
34. Sun X, Xu X, Zhang X. Counterfeit bevacizumab and endophthalmitis (letter). N Engl J Med. 2011;365:378-9.
35. Stein JD, Hanrahan BW, Comer GM, et al. Diffusion of technologies for the care of older adults with exudative age-related macular degeneration. Am J Ophthalmol. 2013;155:688-96.
36. http://www.gene.com/download/pdf/avastin_prescribing.pdf.
37. <http://www.regeneron.com/Eylea/eylea-fpi.pdf>.
38. http://www.gene.com/download/pdf/lucentis_prescribing.pdf.
39. <http://www.bausch.com/Portals/77/-/m/BL/United%20States/Files/Package%20Inserts/Pharma/macugen-package-insert.pdf?ver=2017-02-14-083844-843>.
40. Medi-Span.
41. https://www.healthnet.com/static/general/unprotected/html/national/pa_guidelines/visudyne_natl.html.
42. <http://www.priorityhealth.com/-/media/E7F3DF05EBB240EAB4DDDC62953BE1B8.pdf>.
43. <http://blue.regence.com/trgmedpol/drugs/dru267.pdf>.
44. <http://blue.regence.com/trgmedpol/drugs/dru242.pdf>.
45. <http://blue.regence.com/trgmedpol/drugs/dru241.pdf>.

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.



MEDICATION POLICY

Historical Tracking Of Changes Made To Policy	
1/16/2018	<p>1. Added “I. D. Diabetic Retinopathy (DR) in Patients without DME AND one of criteria 1 through 2 is met: 1. Request is for Avastin®; 2. Request is for Lucentis® AND criterion a is met: a. Documented trial and failure of, intolerance to, or contraindication to Avastin®” under Prior Authorization Criteria.</p>
3/20/2017	<p>1. Changed “Avastin” to “Avastin®” throughout document.</p> <p>2. Changed “I. Documented diagnosis of one of the following conditions A through D...” to “I. Documented diagnosis of one of the following conditions A through E...” and added “I. E. Myopic Choroidal Neovascularization (mCNV) AND one of criteria 1 or 2 is met: 1. Request is for Avastin®; 2. Request is for Lucentis® and criterion a is met: a. Documented trial and failure of, intolerance to, or contraindication to Avastin®” under Prior Authorization Criteria.</p> <p>3. Changed “Authorization: 1 year; Re-Authorization: An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective” to “Authorization: mCNV: Lucentis®: 3 months; Avastin®: 1 year; AMD, DME, RVO, DR: 1 year; Re-Authorization: An updated letter of medical necessity or progress notes showing current medical necessity criteria are met and that the medication is effective. Reauthorization is for the same length as the original authorization” under Approval Length.</p> <p>4. Updated “Diabetic retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2014. Available at: www.aao.org/ppp” to “Diabetic retinopathy. San Francisco, CA: American Academy of Ophthalmology; 2016. Available at: www.aao.org/ppp”, “http://www.bausch.com/Portals/107/-/m/BL/United%20States/USFiles/Package%20Inserts/Pharma/macugen-package-insert.pdf” to “http://www.bausch.com/Portals/77/-/m/BL/United%20States/Files/Package%20Inserts/Pharma/macugen-package-insert.pdf?ver=2017-02-14-083844-843”, and “https://www.priorityhealth.com/~/-/media/documents/drug-auth-forms/d-h/eylea-pa-commercial-medicaid.pdf” to “http://www.priorityhealth.com/~/-/media/E7F3DF05EBB240EAB4DDDC62953BE1B8.pdf” under References.</p>

Disclaimer: Medication Policies are developed to help ensure safe, effective and appropriate use of selected medications. They offer a guide to coverage and are not intended to dictate to providers how to practice medicine. Refer to Plan for individual adoption of specific Medication Policies. Providers are expected to exercise their medical judgment in providing the most appropriate care for their patients.